Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis

Authors


  • Funding
    This study was supported by Pfizer and the initiative ‘Cátedra Universidad Autónoma Madrid-Pfizer de docencia e investigación en la psoriasis’.

  • Disclaimer
    A.J. Blasco and M.D. Aguilar work as researchers in TAISS; TAISS has received funding from Pfizer for methodological assistance in the project development and manuscript elaboration. E. Daudén, S. Castañeda, C. Suárez, J. García Campayo, C. Ferrándiz, L. Puig and J.L. Sánchez-Carazo were paid consultants to Pfizer in connection with the development of this manuscript.

  • Conflicts of Interest
    E. Daudén has been an advisory board member, received grants and research support, participated in clinical trials and received speakers’ fees from the following pharmaceutical companies: Abbott, Astellas, Biogen, Centocor Ortho Biotech Inc., Galderma, Glaxo, Janssen-Cilag, Leo Pharma, MSD, Pfizer, Novartis, Stiefel, Wyeth Pharmaceuticals, 3M and Celgene. S. Castañeda has received education and research support and consultancy fees and speakers’ fees from the following pharmaceutical companies: Abbott, Amgen, Bristol Myers Squibb, MSD, Novartis, Pfizer and Roche. C. Suárez has received education and research support and consultancy and speakers’ fees from the following pharmaceutical companies: Bristol Myers Squibb, MSD, Pfizer, Glaxo, Leo Pharma, Novartis, Sanofi, Almirall, Bayer, Boheringer, Esteve, Ferrer and Janssen-Cilag. Javier Garcia Campayo has received grants and speakers’ fees from the following pharmaceutical companies: Lilly, Esteve, Janssen, Pfizer, Glaxo and Servier. C. Ferrándiz has been an advisory board member, received research support, participated in clinical trials and received consultancy and speakers’ fees from the following pharmaceutical companies: Abbott, Centocor Ortho Biotech Inc, Janssen-Cilag, MSD, Pfizer, Novartis, Wyeth Pharmaceuticals and Celgene. L. Puig has received education and research support and consultancy and speakers’ fees from the following pharmaceutical companies: Abbott, Amgen, Celgene, Janssen, MSD, Novartis and Pfizer. J.L Sanchez Carazo has been an advisory board member, received grants and research support, participated in clinical trials and received speakers’ fees from the following pharmaceutical companies: Abbott, Janssen-Cilag, Leo Pharma, MSD, Pfizer and Novartis. The other authors declare no conflicts of interest.

Abstract

Background  The relationship between psoriasis and associated diseases has drawn particular interest in recent years. To provide appropriate management of psoriasis from an early stage, it is necessary to include prompt diagnosis of concomitant disease and to prevent and treat any comorbidity found. Such an integrated approach also serves to ensure that the drugs used to treat associated diseases do not interfere with the management of psoriasis, and vice versa.

Objective  To provide the dermatologist a guide focuses specifically on the diagnosis and management of the diseases most often found in patients with psoriasis.

Methods  The selection of the diseases, and corresponding supporting research, to be included was based on a systematic review of the literature. The recommendations on diagnostic criteria are based on the main clinical practice guidelines for each of the diseases discussed as well as on the recommendations of a clinical expert advisory group. The information regarding the repercussions of psoriasis treatments on associated comorbid diseases was obtained from the summary of product characteristics of each drug. In turn, the statements concerning the impact of the associated diseases, and their treatment, on psoriasis are based on the review of the literature.

Results  This guide is a precise, easy-to-use tool for systematizing the diagnosis of comorbidity in patients with psoriasis and facilitate decision making regarding referral and treatment of patients diagnosed with an associated disease.

Conclusion  The application of this guide not only will benefit psoriasis patients’ health and quality of life but it will also optimize available resources.

Ancillary